ACHIEVE-2 (NCT06192108) A comparator trial evaluating orforglipron versus dapagliflozin (an SGLT-2 inhibitor) in adults with type 2 diabetes
The conditions that most commonly support eligibility include: Obesity (BMI 30, or 27 with at least one comorbidity such as hypertension, sleep apnea, or cardiovascular disease) Type 2 diabetes or prediabetes Insulin resistance with clinical documentation Metabolic syndrome (clinically diagnosed) Polycystic Metabolic Ovarian Syndrome (PMOS) and related hormonal disorders Non-alcoholic fatty liver disease (NAFLD/MASLD) Perimenopause-related metabolic dysfunction with documented hormonal changes GLP-1 receptor agonists including semaglutide, tirzepatide, and retatrutide are the most commonly used peptides in metabolic care today
Whilst mild nausea and altered appetite are expected effects of Wegovy, severe or prolonged symptoms may require dose adjustment or additional management strategies
Tesamorelin, however, isnt a GLP-1 RA and currently isnt offered by many leading telehealth platforms such as Hims, Hers, Eden, Henry Meds, or Strut
Front Aging 5:1339317
doi: 10.5009/gnl15510 104 FlochPMegraudFLehoursP
